IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

被引：0

作者：

Miller, M. ^{[1
]}

Sahin, U. ^{[2
]}

Derhovanessian, E. ^{[3
]}

Kloke, B-P. ^{[1
]}

Simon, P. ^{[4
]}

Bukur, V. ^{[5
]}

Albrecht, C. ^{[6
]}

Paruzynski, A. ^{[5
]}

Loewer, M. ^{[7
]}

Kuhn, A. ^{[8
]}

Schreeb, K. ^{[9
]}

Attig, S. ^{[10
]}

Brueck, A. Kemmer ^{[9
]}

Bolte, S. ^{[9
]}

Grabbe, S. ^{[11
]}

Hoeller, C. ^{[12
]}

Utikal, J. ^{[13
]}

Huber, C. ^{[14
]}

Loquai, C. ^{[11
]}

Tuereci, O. ^{[15
]}

机构：

[1] Biopharmaceut New Technol BioNTech Corp, Project Management, Mainz, Germany

[2] Biopharmaceut New Technol BioNTech Corp, Management, Mainz, Germany

[3] Biopharmaceut New Technol BioNTech Corp, Immunomonitoring, Mainz, Germany

[4] Biopharmaceut New Technol BioNTech Corp, Immunoreceptor Validat, Mainz, Germany

[5] Biopharmaceut New Technol BioNTech Corp, Genom, Mainz, Germany

[6] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Genom, Mainz, Germany

[7] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Bioinformat, Mainz, Germany

[8] Biopharmaceut New Technol BioNTech Corp, RNA Biochem, Mainz, Germany

[9] Biopharmaceut New Technol BioNTech Corp, Clin Res, Mainz, Germany

[10] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Immunmonitoring, Mainz, Germany

[11] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dermatol, Mainz, Germany

[12] Med Univ Vienna, Dermatol, Vienna, Austria

[13] German Canc Res Ctr, Dermatol, Heidelberg, Germany

[14] Biopharmaceut New Technol BioNTech Corp, Advisory Board, Mainz, Germany

[15] CI3 Cluster Individualized Immunointervent, Management, Mainz, Germany

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[41] An open-label, first-in-human, phase I trial of the safety and efficacy of daily PCLX-001. [J].

Sangha, Randeep S. ;

Sehn, Laurie Helen ;

Kuruvilla, John ;

Weickert, Michael ;

Mackey, John Robert ;

Berthiaume, Luc G. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[42] The Novel Nucleoside Analogue ProTide NUC-7738 Overcomes Cancer Resistance Mechanisms In Vitro and in a First-In-Human Phase I Clinical Trial [J].

Schwenzer, Hagen ;

De Zan, Erica ;

Elshani, Mustafa ;

van Stiphout, Ruud ;

Kudsy, Mary ;

Morris, Josephine ;

Ferrari, Valentina ;

Um, In Hwa ;

Chettle, James ;

Kazmi, Farasat ;

Campo, Leticia ;

Easton, Alistair ;

Nijman, Sebastian ;

Serpi, Michaela ;

Symeonides, Stefan ;

Plummer, Ruth ;

Harrison, David J. ;

Bond, Gareth ;

Blagden, Sarah P. .

CLINICAL CANCER RESEARCH, 2021, 27 (23) :6500-6513

[43] A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas [J].

Del Rivero, Jaydira ;

Glod, John ;

Magee, Tamika ;

Cooper, Kimberley ;

Rivero, Anna ;

Lanfranconi, Tea ;

Patel, Rashmika ;

Figg, W. Douglas ;

Pommier, Yves ;

Widemann, Brigitte C. ;

Roper, Nitin .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) :TPS672-TPS672

[44] Volunteer feedback and perceptions after participation in a phase I, first-in-human Ebola vaccine trial: An anonymous survey [J].

Dayer, Julie-Anne ;

Siegrist, Claire-Anne ;

Huttner, Angela .

PLOS ONE, 2017, 12 (03)

[45] FIRST-IN-HUMAN PHASE I TRIAL OF IBI188, AN ANTI-CD47 TARGETING MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS [J].

Lakhani, Nehal ;

Orloff, Marlana ;

Fu, Siqing ;

Liu, Ying ;

Wang, Yan ;

Zhou, Hui ;

Lin, Kedan ;

Liu, Fang ;

Yan, Shuling ;

Patnaik, Amita .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 :A180-A180

[46] First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors [J].

Christopher B. Cole ;

Maria Pia Morelli ;

Massimo Fantini ;

Markku Miettinen ;

Patricia Fetsch ;

Cody Peer ;

William D. Figg ;

Tyler Yin ;

Nicole Houston ;

Ann McCoy ;

Stanley Lipkowitz ;

Alexandra Zimmer ;

Jung-min Lee ;

Miroslava Pavelova ;

Erin N. Villanueva ;

Kathryn Trewhitt ;

B. Brooke Solarz ;

Maria Fergusson ;

Sharon A. Mavroukakis ;

Anjum Zaki ;

Kwong Y. Tsang ;

Philip M. Arlen ;

Christina M. Annunziata .

Journal of Experimental & Clinical Cancer Research, 42

[47] Immunological effects of checkpoint blockade plus galectin-3 inhibition with GR-MD-02 in a first-in-human phase I clinical trial [J].

Redmond, William ;

Koguchi, Yoshinobu ;

Fountain, Christopher d ;

Traber, Peter ;

Curti, Brendan .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5

[48] Choice of Starting Dose for Molecularly Targeted Agents Evaluated in First-in-Human Phase I Cancer Clinical Trials [J].

Le Tourneau, Christophe ;

Stathis, Anastasios ;

Vidal, Laura ;

Moore, Malcolm J. ;

Siu, Lillian L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1401-1407

[49] A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2 [J].

Flanigan, Kevin M. ;

Vetter, Tatyana A. ;

Simmons, Tabatha R. ;

Iammarino, Megan ;

Frair, Emma C. ;

Rinaldi, Federica ;

Chicoine, Louis G. ;

Harris, Johan ;

Cheatham, John P. ;

Cheatham, Sharon L. ;

Boe, Brian ;

Waldrop, Megan A. ;

Zygmunt, Deborah A. ;

Packer, Davin ;

Martin, Paul T. .

MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2022, 27 :47-60

[50] Safety and Efficacy Results of BonoFill First-in-Human, Phase I/IIa Clinical Trial for the Maxillofacial Indication of Sinus Augmentation and Mandibular Bone Void Filling [J].

Tzur, Ephraim ;

Ben-David, Dror ;

Barzilai, Maya Gur ;

Rozen, Nimrod ;

Meretzki, Shai .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2021, 79 (04) :787-+

← 1 2 3 4 5 →